ASH 2010 - Orlando - CML - Chronic Myeloid Leukemia
52nd ASH Annual Meeting and Exposition - Program for CML
NEWS
Dasatinib moves ahead of imatinib as front-line therapy for newly diagnosed CML in chronic phase
December 7, 2010, CancerNetwork.com
Nilotinib exerts positive effect in early chronic phase Ph+ CML
December 7, 2010, CancerNetwork.com
ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
December 7, 2010, Thepharmaletter
ASH: New CML Drug Still Beating Out Its Predecessor
December 7, 2010, Medpage Today
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat
ASH: Early assessment of molecular response identified increased risk for treatment failure in CML
December 6, 2010, Hemonctoday
Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010, Hemonctoday
Dasatinib moves ahead of imatinib as front-line therapy for newly diagnosed CML in chronic phase
December 7, 2010, CancerNetwork.com
Nilotinib exerts positive effect in early chronic phase Ph+ CML
December 7, 2010, CancerNetwork.com
ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
December 7, 2010, Thepharmaletter
ASH: New CML Drug Still Beating Out Its Predecessor
December 7, 2010, Medpage Today
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
December 6, 2010, Oncology Stat
ASH: Early assessment of molecular response identified increased risk for treatment failure in CML
December 6, 2010, Hemonctoday
Nilotinib associated with stable outcomes in Ph+CML
December 4, 2010, Hemonctoday
NOTES
Abstracts and notes on CML presentations by Prof Steve O’Brien
2010, SPIRIT2, NewCastle Universisty
Abstracts and notes on CML presentations by Prof Steve O’Brien
2010, SPIRIT2, NewCastle Universisty
PATIENTS ASSOCIATIONS
ASH 2010 Report: A new era in first line CML treatment coming up?
December 15, 2010 , CML Advocates Network
ASH 2010 Report: A new era in first line CML treatment coming up?
December 15, 2010 , CML Advocates Network
ARTICLES
Persistence of BCR-ABL-Expressing leukemic stem cells in chronic myeloid leukemia (CML) patients in complete remission with undetectable molecular disease
December 7, 2010, ASH 2010
ASH 2010: JAK2-Mediated Extrinsic Survival of CML Stem Cells: Exploring the Potential Combination of BCR-ABL and JAK2 Inhibitors In Vivo
December 6, 2010, ASH2010
Distinct Impact of Imatinib on Growth In Prepubertal and Pubertal Children with Chronic Myeloid Leukemia
December 5, 2010, ASH2010
Persistence of BCR-ABL-Expressing leukemic stem cells in chronic myeloid leukemia (CML) patients in complete remission with undetectable molecular disease
December 7, 2010, ASH 2010
ASH 2010: JAK2-Mediated Extrinsic Survival of CML Stem Cells: Exploring the Potential Combination of BCR-ABL and JAK2 Inhibitors In Vivo
December 6, 2010, ASH2010
Distinct Impact of Imatinib on Growth In Prepubertal and Pubertal Children with Chronic Myeloid Leukemia
December 5, 2010, ASH2010
